Specialized Melanoma Treatment Solutions for Unique Operational Environments

Publication ID: 24-11857529_0009_PTD
Published: October 28, 2025
Category:Specialized Variations & Niche Solutions

Legal Citation

pr1or.art Inc., “Specialized Melanoma Treatment Solutions for Unique Operational Environments,” Published Technical Disclosure No. 24-11857529_0009_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857529_0009_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,529.

Summary of the Inventive Concept

The present inventive concept adapts the original melanoma treatment method using dapansutrile for specific, narrow markets or unique operational environments, addressing high-security needs, disaster relief, extreme weather conditions, and other niche scenarios.

Background and Problem Solved

The original patent disclosed a method for treating melanoma using dapansutrile. However, it did not address the challenges of administering this treatment in high-security environments, disaster-stricken areas, or extreme weather conditions. The present inventive concept solves this problem by providing specialized solutions tailored to these unique operational environments.

Detailed Description of the Inventive Concept

The inventive concept comprises four main variations: (1) a secure, tamper-evident delivery system for high-security environments; (2) a dapansutrile-based treatment module designed for disaster relief in extreme weather conditions; (3) a portable, weather-resistant dapansutrile delivery device for remote, extreme-weather locations; and (4) a kit for treating melanoma in high-altitude, low-oxygen environments. Each variation is tailored to address the specific challenges of its target operational environment.

Novelty and Inventive Step

The present inventive concept introduces novel features not present in the original patent, including secure delivery systems, disaster relief modules, and portable delivery devices designed for extreme weather conditions. These features provide a non-obvious solution to the problem of administering melanoma treatment in unique operational environments.

Alternative Embodiments and Variations

Other embodiments of the inventive concept could include adapting the treatment module for use in high-temperature or high-humidity environments, or integrating the dapansutrile delivery device with other medical equipment for disaster relief scenarios.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of disaster relief, high-security medical services, and extreme weather condition medical response. Target industries include government agencies, non-profit organizations, and private companies operating in these niches.

Field of Art

Oncological pharmacology and medical treatment methods, specifically melanoma therapeutics, requiring advanced knowledge of pharmaceutical formulation, drug delivery systems, and medical treatment protocols

Person of Ordinary Skill (PHOSITA) Profile

A medical researcher or pharmaceutical development specialist with expertise in oncology, drug delivery technologies, and clinical treatment adaptation for specialized environments, holding advanced degrees in pharmacology or medical sciences

Obviousness Rationale

A PHOSITA would recognize that the PTD's variations represent predictable extensions of the source patent's core melanoma treatment method using dapansutrile, applying standard pharmaceutical engineering techniques to adapt drug delivery for specific operational contexts. The disclosed variations demonstrate routine problem-solving approaches typical in medical technology adaptation, utilizing known design principles for specialized treatment scenarios. Each variation maintains the fundamental treatment method while introducing contextual modifications that would be considered obvious design choices within pharmaceutical engineering.

Obvious Combinations & Variations

Source Patent Element
Systemic administration of dapansutrile for melanoma treatment
PTD Variation
Secure, tamper-evident delivery system for high-security environments
Obviousness Reasoning
Adapting existing drug delivery mechanisms to secure environments represents a predictable design variation using known pharmaceutical packaging and security technologies
Source Patent Element
Oral administration method for melanoma treatment
PTD Variation
Portable, weather-resistant dapansutrile delivery device for remote locations
Obviousness Reasoning
Modifying drug delivery mechanisms for environmental resilience is a standard engineering approach addressing known limitations in medical treatment deployment
Source Patent Element
Treatment method targeting specific melanoma types
PTD Variation
Specialized treatment kit for high-altitude, low-oxygen environments
Obviousness Reasoning
Incorporating supplemental oxygen and adapting treatment protocols for specific physiological conditions represents a routine medical engineering problem-solving approach
Source Patent Element
Melanoma treatment using dapansutrile
PTD Variation
Disaster relief treatment module designed for extreme weather conditions
Obviousness Reasoning
Developing robust medical treatment solutions for challenging environments is a predictable extension of standard pharmaceutical engineering practices
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857529 and the published technical disclosure, a person having ordinary skill in the art would find the claimed variations in medical treatment delivery methods obvious and anticipated, as the disclosed adaptations represent routine engineering modifications to the fundamental melanoma treatment method using dapansutrile, applying standard pharmaceutical development techniques to address specific operational constraints.

Original Patent Information

Patent NumberUS 11,857,529
TitleMethods for treating melanoma
Assignee(s)OLATEC THERAPEUTICS, INC.